Cullinan Therapeutics (CGEM) News Today $17.94 +0.71 (+4.12%) (As of 09/19/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period Cullinan Therapeutics (NASDAQ:CGEM) Earns Outperform Rating from WedbushSeptember 20 at 3:57 AM | americanbankingnews.comAustralian HREC grants clearance for Cullinan Therapeutics’ SLE treatment trialSeptember 19 at 5:22 PM | msn.comCullinan Management (CGEM) Gets a Buy from WedbushSeptember 19 at 2:17 AM | markets.businessinsider.comE Fund Management Co. Ltd. Purchases New Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)E Fund Management Co. Ltd. purchased a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 74,827 shares of the company's stock, valueSeptember 18 at 6:12 AM | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Up 5.5%Cullinan Therapeutics (NASDAQ:CGEM) Trading 5.5% HigherSeptember 17 at 3:16 PM | marketbeat.comCullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus ErythematosusSeptember 17 at 7:00 AM | globenewswire.comCullinan Therapeutics (NASDAQ:CGEM) Given Buy Rating at HC WainwrightSeptember 17 at 5:31 AM | americanbankingnews.comContrasting Cullinan Therapeutics (NASDAQ:CGEM) and CARGO Therapeutics (NASDAQ:CRGX)September 17 at 3:39 AM | americanbankingnews.comBank of New York Mellon Corp Buys 43,757 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Bank of New York Mellon Corp raised its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 46.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 137,997 shares of the coSeptember 17 at 3:10 AM | marketbeat.comBrokerages Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Price Target at $32.00September 17 at 1:35 AM | americanbankingnews.comTD Cowen Keeps Their Buy Rating on Cullinan Management (CGEM)September 16, 2024 | markets.businessinsider.comCullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up to $17.95Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up to $17.95September 16, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $28.00 price objective on shares of Cullinan Therapeutics in a research note on Monday.September 16, 2024 | marketbeat.comCullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024September 14, 2024 | globenewswire.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by BrokeragesShares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have been given an average recommendation of "Buy" by the six research firms that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month target prSeptember 14, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 8,000 SharesSeptember 10, 2024 | insidertrades.comInsider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 8,000 Shares of StockCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 8,000 shares of the company's stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $18.09, for a total value of $144,720.00. Following the transaction, the insider now directly owns 115,942 shares in the company, valued at approximately $2,097,390.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.September 9, 2024 | marketbeat.comCullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune DiseaseAugust 30, 2024 | seekingalpha.comCullinan Therapeutics to Participate in Upcoming Investor ConferencesAugust 28, 2024 | globenewswire.comWe Think Cullinan Therapeutics (NASDAQ:CGEM) Can Afford To Drive Business GrowthAugust 24, 2024 | finance.yahoo.comAssenagon Asset Management S.A. Invests $1.99 Million in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Assenagon Asset Management S.A. acquired a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 114,195 shares ofAugust 22, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Up 3.6%Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 3.6%August 21, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest Up 6.0% in JulyCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totalling 8,360,000 shares, an increase of 6.0% from the July 15th total of 7,890,000 shares. Based on an average trading volume of 838,400 shares, the short-interest ratio is presently 10.0 days. Approximately 20.6% of the company's shares are short sold.August 18, 2024 | marketbeat.comCullinan Therapeutics, Inc. (CGEM)August 18, 2024 | finance.yahoo.comSG Americas Securities LLC Increases Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)SG Americas Securities LLC boosted its holdings in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 757.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 85,172 shares of the compaAugust 16, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Rating Reiterated by WedbushWedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Cullinan Therapeutics in a research report on Thursday.August 8, 2024 | marketbeat.comCullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | uk.finance.yahoo.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Position Cut by American International Group Inc.American International Group Inc. trimmed its stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 99.0% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 12,742 shares of the company's stock after selling 1,223,822 shares during the quartAugust 2, 2024 | marketbeat.comKennedy Capital Management LLC Sells 75,778 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Kennedy Capital Management LLC trimmed its holdings in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 47.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,234 shares of the company's stock afAugust 1, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Buy" by AnalystsCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) has received a consensus recommendation of "Buy" from the six ratings firms that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price objective among brokersJuly 26, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Up 5.7%Cullinan Therapeutics (NASDAQ:CGEM) Trading 5.7% HigherJuly 22, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 8.1%Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 8.1%July 17, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Trading Up 7.2%Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 7.2%July 16, 2024 | marketbeat.comShort Interest in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Increases By 73.5%Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 7,840,000 shares, a growth of 73.5% from the June 15th total of 4,520,000 shares. Based on an average trading volume of 976,600 shares, the short-interest ratio is presently 8.0 days. Currently, 19.3% of the company's shares are short sold.July 12, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 5%Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 5%July 2, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of "Buy" by AnalystsShares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have earned an average recommendation of "Buy" from the six ratings firms that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 yeJuly 1, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 5.5%Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 5.5%June 18, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Large Increase in Short InterestCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 4,340,000 shares, an increase of 16.0% from the May 15th total of 3,740,000 shares. Currently, 11.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 782,700 shares, the days-to-cover ratio is currently 5.5 days.June 16, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC grew its stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 20.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 529,877 shares of the company's stJune 13, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.9% Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 2.9%June 12, 2024 | marketbeat.comBraidwell LP Sells 668,000 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Braidwell LP cut its position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 35.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,240,865 shares of the company's stock after selling 668,000 shares during the period. Braidwell LP owned approJune 12, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Trading 4% Higher Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 4%June 11, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Gap Down to $22.40Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Down to $22.40June 10, 2024 | marketbeat.comChecking Into Cullinan TherapeuticsJune 9, 2024 | seekingalpha.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Buy" from AnalystsCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) has been given an average rating of "Buy" by the seven analysts that are currently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price target among bJune 6, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up to $22.40Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up to $22.40June 5, 2024 | marketbeat.comAffinity Asset Advisors LLC Makes New Investment in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Affinity Asset Advisors LLC bought a new position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 300,000 shares of the company's stockJune 5, 2024 | marketbeat.comTrexquant Investment LP Makes New $356,000 Investment in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Trexquant Investment LP purchased a new position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 34,955 shares of the company's stock, valued atJune 4, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Earns "Outperform" Rating from William BlairWilliam Blair reaffirmed an "outperform" rating on shares of Cullinan Therapeutics in a report on Monday.June 3, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Gap Down to $23.50Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Down to $23.50June 3, 2024 | marketbeat.com Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Must-Know for Trading Options (Ad)Options are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a row! But – knowing what the options trading landscape looks like, and what you're up against is a must. So make sure you claim your free seat by clicking here now. CGEM Media Mentions By Week CGEM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEM News Sentiment▼0.460.40▲Average Medical News Sentiment CGEM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEM Articles This Week▼172▲CGEM Articles Average Week Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XNCR News BDTX News MGNX News IPHA News TGTX News BHVN News MLTX News RYTM News XENE News DYN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEM) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersAct by Friday, August 16th, to collect this 22% dividendLet's do a little math here... To double your money at a 3% rate of return, you would need around 23 years....Investors Alley | SponsoredWhy You Should NOT Trade This MarketYou'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this dif...InvestorPlace | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
